LEAPS-H1N1

LEAPS-H1N1 is an investigational **peptide immunotherapy vaccine** built on CEL-SCI's Ligand Epitope Antigen Presentation System platform for pandemic influenza A, particularly H1N1. The construct links a T-cell binding ligand to influenza peptide epitopes derived from conserved, relatively non-changing regions of influenza A, with the goal of directing an antigen-specific cellular immune response rather than relying solely on strain-matched neutralizing antibodies. Public company and program materials indicate it was explored both as a direct peptide-based therapeutic vaccine and as an ex vivo dendritic-cell-based product candidate referred to as LEAPS-H1N1-DC for hospitalized patients with pandemic influenza. The program appears to have remained investigational and preclinical to very early clinical-stage, with no approved product identified.

Other names

Ligand Epitope Antigen Presentation System H1N1H1N1 LEAPS vaccineH-1N1 LEAPS vaccineH 1N1 LEAPS vaccineH1N1 LEAPS immunotherapyH-1N1 LEAPS immunotherapyH 1N1 LEAPS immunotherapy